CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

BuenTrip Ventures

Fernando Rivera, Managing Partner

The Changing Geography of the Venture Capital

Fernando Rivera

Fernando Rivera

With close to $16 billion invested, venture capital in Latin America enjoyed a record year in 2021, more than tripling the previous record set in 2019. However, venture capital investment in Latin America remains heavily concentrated despite record growth.


Brazil accounts for almost half of the total invested capital and stands in a league of its own. Five countries account for nearly 95 percent of all investments, with 30 percent of the region's GDP receiving less than 5 percent of invested capital.


This concentration of investment creates an opportunity for investors willing to invest in non-traditional markets and non-elite founders.


According to data compiled by the Association for Latin American Private Capital Investment in Latin America (LAVCA), 2021 shattered all records in Venture Capital with $15.7 million invested in over 856 deals. This number will only continue to grow as the number of VC funds grew 65 percent from the previous year to 49 and the amount raised by funds grew by 41 percent to $2.4 billion.


There are many reasons for this growth. As Atlantico's 2021 Latin American Digital Transformation Report highlights: Latin America is home to 8 percent of the world's population and represents 5 percent of global GDP. Latin Americans are the world's heaviest users of the internet, and COVID accelerated the pace of digital transformation, bringing millions of users online.


The number of unicorns has doubled every year since 2018. However, there is still room for growth, considering that the market cap of tech companies in the region still only represents 3.4 percent of GDP, compared to 14.2 percent in India and 30.x percent in China.


Despite the accelerating growth in VC, some structural issues create a highly concentrated market for venture capital.


Although they only represent 50 percent of the regions' GDP, Brazil and Mexico accounted for over 70 percent of investments in 2021. Other countries with a sizable share of the pie are Colombia, Chile, and Argentina. This distribution of venture capital makes sense because these are the largest markets in Latin America and allow for venture-scale growth.


“Despite the accelerating growth in VC, some structural issues create a highly concentrated market for venture capital”


However, scaling a software-based company throughout Latin America is more accessible than in other regions. Brazil aside, the region's countries share a common language, culture, and legal structures. Fast scaling companies can be born anywhere on the continent. A tiny country like Uruguay, with a population of 4 million, has produced two unicorns (dLocal, PedidosYa) and could. Ecuador could soon have its first unicorn (Kushki) and potentially a second (Inspectorio).


I'm not saying that scaling a tech company in Latin America is trivial. Founders face significant friction, including high costs of doing business, bureaucracy, and even government corruption. However, it is becoming increasingly easy to expand.


Latin American founders can find and attract talent throughout the region. Covid made building remote teams a necessity, and companies like Torre, Deel, and Ontop make it incredibly easy to build and scale remote teams.


Latitude just announced an $11 million seed round led by Andreesen and NFX to create the platform startups need to lower the costs of building a venture-backed business.


Despite the accelerating growth in VC, some structural issues create a highly concentrated market for venture capital


Venture capital is a relatively new industry globally. Over the past decade or so, it has grown tremendously from its Silicon Valley origins to span the whole world. Perhaps it is only time before it reaches all geographies.


Arbitrarily deciding to only source deals in Mexico City or Sao Paulo is a lazy approach. For those more enterprising investors interested in Latin America, it would pay to look outside of the traditional hubs for amazing founders building amazing companies.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/the-changing-geography-of-the-venture-capital-nwid-821.html